First generic alternative to Eliquis® now available in Canada
by CM Staff
Apotex says it remains committed to bringing more generics to Canadian patients.
Apotex Inc – Innovating for Patient Affordability Logo (CNW Group/Apotex Inc.)
TORONTO — Canadian pharmaceutical manufacturer of generic medicines, Apotex Inc. has launched APO-ApixabanTM tablets and has called it the country’s first generic alternative to Eliquis®.
Apotex’s apixaban is an oral anticoagulant indicated for the prevention and treatment of harmful blood clots. Available in 2.5 mg and 5mg tablets, this product comes in multiple package sizes including 60, 180, and 500 BTL.
“It is with great pride that we launch APO-ApixabanTM,” said Raymond Shelley, SVP, commercial operations, Canada & Rest of World Markets in a statement.
“Gaining access to a generic option of an important medication like Eliquis® provides patients with more affordable opportunities for the treatment of blood clots.”
Anticoagulants, also known as blood thinners, are administered to patients who are at a high risk of getting blood clots, to reduce their chances of developing serious conditions such as strokes and heart attacks.
The pharmaceutical manufacturer says APO-ApixabanTM adds to their anticoagulant portfolio, which currently includes APO-Dabigatran.
Apotex says it remains committed to bringing more generics to Canadian patients.
